Anti-malaria drug hydroxychloroquine championed by Donald Trump for coronavirus COVID-19 treatment fails another test, finds study

Anti-malaria drug hydroxychloroquine championed by Donald Trump for coronavirus COVID-19 treatment fails another test, finds study

A new study has revealed that anti-malaria drug Hydroxychloroquine (HCQ) has failed another test to prove its efficiency in treating the coronavirus COVID-19, with infected patients showing no change in their conditions after being administered HCQ. The observational study was published in the New England Journal of Medicine (NEJM). The study found that the use of HCQ failed to reduce the need for patients requiring breathing assistance and it also has no effect on decreasing the risk of death. The NEJM study, however, showed that HCQ had no potential harm too.

Notably, observational studies are not considered as conclusive as randomized-controlled trials because several drugs and therapies are often used by clinicians to treat patients. The NEJM study asserted that the effectiveness of the HCQ could only be established by rigorous clinical trials. The study was funded by the US National Institutes of Health.

On April 9, President Trump had thanked India and Prime Minister Narendra Modi for allowing the export of hydroxychloroquine to the US. “Extraordinary times require even closer cooperation between friends. Thank you India and the Indian people for the decision on HCQ. It Will not be forgotten! Thank you, PM Modi, for your strong leadership in helping not just India, but humanity, in this fight!” he had tweeted. The US is now pushing antiviral drug Remdesivir manufactured by Gilead Sciences to treat COVID-19 and Remdesivir has now become the first drug to get emergency use authorization in the US for coronavirus treatment.